These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 28936893)

  • 1. Severe hypertrophic cardiomyopathy in a patient with atypical Anderson-Fabry disease.
    Masarone D; Duro G; Dellegrottaglie S; Colomba P; Rubino M; Cirillo A; Pisani A; Caiazza M; Elliott PM; Calabrò P; Pacileo G; Limongelli G
    Future Cardiol; 2017 Nov; 13(6):521-527. PubMed ID: 28936893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cardiac imaging in Anderson-Fabry cardiomyopathy.
    Serra W; Marziliano N
    Cardiovasc Ultrasound; 2019 Jan; 17(1):1. PubMed ID: 30674321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The heart in Anderson Fabry disease.
    Kampmann C; Wiethoff CM; Perrot A; Beck M; Dietz R; Osterziel KJ
    Z Kardiol; 2002 Oct; 91(10):786-95. PubMed ID: 12395219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of an Implantable Loop Recorder to Detect Clinically Relevant Arrhythmias in Patients With Advanced Fabry Cardiomyopathy.
    Weidemann F; Maier SK; Störk S; Brunner T; Liu D; Hu K; Seydelmann N; Schneider A; Becher J; Canan-Kühl S; Blaschke D; Bijnens B; Ertl G; Wanner C; Nordbeck P
    Am J Cardiol; 2016 Jul; 118(2):264-74. PubMed ID: 27265676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe Late-Onset Fabry Cardiomyopathy Unmasked by a Multimodality Imaging Approach.
    Visoiu IS; Ciobanu AO; Nicula AI; Iascone M; Jurcut R; Vinereanu D; Rimbas RC
    Circ Cardiovasc Imaging; 2019 Nov; 12(11):e009709. PubMed ID: 31630529
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cardiological follow-up in patients with Fabry disease].
    Pieruzzi F; Pieroni M; Chimenti C; Frustaci A; Sarais C; Cecchi F;
    G Ital Cardiol (Rome); 2010; 11(7-8):566-72. PubMed ID: 21033333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac involvement in Anderson-Fabry disease.
    Cauti FM; O'Mahony C; Pantazis A
    BMJ Case Rep; 2010 Aug; 2010():. PubMed ID: 22767366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
    J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
    Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
    Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implantable cardioverter defibrillator therapy and sudden death risk stratification in hypertrophic cardiomyopathy patients with midventricular obstruction: A single-center experience.
    Maeda R; Minami Y; Haruki S; Kanbayashi K; Itani R; Suzuki A; Ejima K; Shiga T; Shoda M; Hagiwara N
    Int J Cardiol; 2016 Jul; 214():419-22. PubMed ID: 27088403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fabry disease in cardiology practice: Literature review and expert point of view.
    Hagège A; Réant P; Habib G; Damy T; Barone-Rochette G; Soulat G; Donal E; Germain DP
    Arch Cardiovasc Dis; 2019 Apr; 112(4):278-287. PubMed ID: 30826269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.
    Putko BN; Wen K; Thompson RB; Mullen J; Shanks M; Yogasundaram H; Sergi C; Oudit GY
    Heart Fail Rev; 2015 Mar; 20(2):179-91. PubMed ID: 25030479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
    Vieira AP; Adragão PP; Santos KR; Morgado FB; Cavaco DM; Rossi R; Abecasis M; Neves JP; Bonhosrst D; Gomes JL; Gomes RS
    Rev Port Cardiol; 2005 Mar; 24(3):407-15. PubMed ID: 15929624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Benefit of Cardiac Magnetic Resonance Over Transthoracic Echocardiography for the Assessment of Ischemic and Nonischemic Dilated Cardiomyopathy Patients Referred for the Evaluation of Primary Prevention Implantable Cardioverter-Defibrillator Therapy.
    Pontone G; Guaricci AI; Andreini D; Solbiati A; Guglielmo M; Mushtaq S; Baggiano A; Beltrama V; Fusini L; Rota C; Segurini C; Conte E; Gripari P; Dello Russo A; Moltrasio M; Tundo F; Lombardi F; Muscogiuri G; Lorenzoni V; Tondo C; Agostoni P; Bartorelli AL; Pepi M
    Circ Cardiovasc Imaging; 2016 Oct; 9(10):. PubMed ID: 27729359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
    Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
    Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Athletes with implantable cardioverter defibrillators: can they return to competitive sports?
    Prutkin JM; Ackerman MJ; Drezner JA
    Heart; 2016 Jan; 102(2):93-4. PubMed ID: 26729607
    [No Abstract]   [Full Text] [Related]  

  • 19. [Use of an implantable defibrillator for the prevention of sudden death in hypertrophic cardiomyopathy].
    Hentati M; Ben Ameur I; Kechida Z; Charfeddine H; Hached L; Grati Z; Kammoun S
    Tunis Med; 2003; 81 Suppl 8():675-9. PubMed ID: 14608758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
    Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
    Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.